Cross-ancestry GWAS of more than 1.8 million people flags SERPINA1, SMAD3, and other bronchiectasis targets shared with COPD and chronic bronchitis.
|Articles|March 1, 1997
Supplements and Featured Publications
- Integrating Risk Factor Management of Coronary Heart Disease into Managed Care
- Volume 3
- Issue 3 Suppl
Clinical Implications of Recent Cholesterol Lowering Trials for the Secondary Prevention of Coronary Heart Disease
Author(s)Robert A. Vogel, MD
Advertisement
Articles in this issue
over 29 years ago
Goals and Objectivesover 29 years ago
Introductionover 29 years ago
Risk-Factor Management in Women and Other Special Patientsover 29 years ago
Risk Factor Management: Exploring the Boundariesover 29 years ago
CME Quizover 29 years ago
BibliographyAdvertisement
Related to this article
The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential.
ALIS added to azithromycin and ethambutol raised culture conversion in new MAC lung disease, with rare resistance, in an ENCORE analysis at IDWeek 2026.
A real-world trial found 42.6% of patients with severe hand eczema cleared on oral alitretinoin.
AMCP Nexus 2026 brings managed care leaders to San Diego October 26-29 to tackle Medicare negotiation, drug pricing policy, AI, and patient access.
IDWeek 2026 posters describe a rule-based tool classifying about 1 in 5 patients with cUTI as outpatient-eligible and 5 clusters with varied LOS.
Insmed’s once-daily TPIP prodrug shows sustained lung vasodilation in PAH and PH-ILD, improving walk distance and other key measures.
An international eDelphi panel of 62 dermatologists agreed on a 2-step algorithm for tapering psoriasis biologics.
Advertisement
Advertisement
Trending on AJMC
1
Awareness Gaps Drive Narcolepsy, IH Delays: Logan Schneider, MD
2
Administrative Burden Keeps Clinicians From Bedside: Amy Morris, MD
3
International Panel Agrees on Framework for Tapering Psoriasis Biologics
4
Extension Studies in TPIP Show Promise in PAH, PH-ILD
5